Valuation : Bolt Biotherapeutics, Inc.

Market Cap 7.51M 6.47M 6.08M 5.56M 10.4M 710M 10.43M 71.85M 27.86M 364M 28.21M 27.59M 1.17B P/E 2026 *
-0.17x
P/E 2027 * -0.19x
Enterprise Value 7.51M 6.47M 6.08M 5.56M 10.4M 710M 10.43M 71.85M 27.86M 364M 28.21M 27.59M 1.17B EV / Sales 2026 *
37.6x
EV / Sales 2027 * 2.15x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day+0.13%
1 week+2.23%
Current month-2.01%
1 month-1.27%
3 months-14.47%
6 months-10.34%
Current year-28.68%
1 week 3.8
Extreme 3.8
4.15
1 month 3.13
Extreme 3.13
4.27
Current year 3.13
Extreme 3.13
7.2
1 year 3.13
Extreme 3.13
7.2
3 years 3.13
Extreme 3.13
31.2
5 years 3.13
Extreme 3.13
385.7
10 years 3.13
Extreme 3.13
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2024-05-14
Chief Executive Officer 55 2024-05-14
Chief Operating Officer 61 2024-05-14
Director TitleAgeSince
Director/Board Member 64 2020-11-30
Director/Board Member 55 2024-05-14
Chairman 56 2024-09-03
Date Insider Type Main position Quantity % Market Cap. Importance
6/10/26 Free

Chairman

5,000 0.2602%
1/28/26 Free

Chief Operating Officer

10,000 0.5210%
1/28/26 Buy

Chief Executive Officer

20,125 1.0485%
Change 5-day change 1-year change 3-year change Capi.($)
+0.13%+2.23%-24.86%-82.43% 7.51M
-1.79%-2.27%+50.90%+89.03% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
-3.00%-2.90%+39.40%+9.41% 25.74B
+0.86%+1.65%-7.74%-14.95% 26.06B
-1.46%+0.42%+24.07%-18.70% 20.09B
-2.96%-15.21%+210.71%+370.84% 17.16B
-1.49%-4.88%-0.41%+530.26% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.23%+0.45%+37.46%+151.38% 27.91B
Weighted average by Cap. -1.52%+0.18%+40.85%+137.15%

Financials

2026 *2027 *
Net sales 200K 172K 162K 148K 277K 18.9M 278K 1.91M 742K 9.68M 751K 735K 31.24M 3.5M 3.01M 2.83M 2.59M 4.84M 331M 4.86M 33.48M 12.98M 169M 13.14M 12.86M 547M
Net income -47.4M -40.82M -38.35M -35.06M -65.59M -4.48B -65.82M -453M -176M -2.3B -178M -174M -7.4B -47.5M -40.91M -38.43M -35.13M -65.73M -4.49B -65.95M -454M -176M -2.3B -178M -174M -7.42B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
26-09-04 US$3.900 +0.13% 8,506
26-09-03 US$3.895 +1.43% 5,553
26-09-02 US$3.840 -5.65% 34,539
26-09-01 US$4.070 +2.26% 8,087
26-08-31 US$3.980 +4.33% 4,958
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.900USD
Average target price
29.00USD
Spread / Average Target
+643.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock